These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
521 related items for PubMed ID: 23329465
1. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Lomonaco R, Sunny NE, Bril F, Cusi K. Drugs; 2013 Jan; 73(1):1-14. PubMed ID: 23329465 [Abstract] [Full Text] [Related]
2. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, Sattar N, Fraser A, Waugh N. Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955 [Abstract] [Full Text] [Related]
3. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Stein LL, Dong MH, Loomba R. Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118 [Abstract] [Full Text] [Related]
4. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Cusi K. Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131 [Abstract] [Full Text] [Related]
5. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C. Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870 [Abstract] [Full Text] [Related]
6. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Unalp A, Tonascia J, NASH CRN Research Group. Contemp Clin Trials; 2009 Jan; 30(1):88-96. PubMed ID: 18804555 [Abstract] [Full Text] [Related]
7. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Budd J, Cusi K. Curr Diab Rep; 2020 Oct 05; 20(11):59. PubMed ID: 33015726 [Abstract] [Full Text] [Related]
8. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Smith BW, Adams LA. Nat Rev Endocrinol; 2011 May 10; 7(8):456-65. PubMed ID: 21556019 [Abstract] [Full Text] [Related]
9. Vitamin E and nonalcoholic fatty liver disease. Pacana T, Sanyal AJ. Curr Opin Clin Nutr Metab Care; 2012 Nov 10; 15(6):641-8. PubMed ID: 23075940 [Abstract] [Full Text] [Related]
10. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Ranjbar G, Mikhailidis DP, Sahebkar A. Metabolism; 2019 Dec 10; 101():154001. PubMed ID: 31672448 [Abstract] [Full Text] [Related]
11. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K. Hepatology; 2009 Oct 10; 50(4):1087-93. PubMed ID: 19670459 [Abstract] [Full Text] [Related]
12. State of the art: treatment of nonalcoholic steatohepatitis. Pearlman M, Loomba R. Curr Opin Gastroenterol; 2014 May 10; 30(3):223-37. PubMed ID: 24717764 [Abstract] [Full Text] [Related]
13. [Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis]. Heebøll S, Kazankov K, Poulsen MK, Vilstrup H, Grønbæk H. Ugeskr Laeger; 2012 Feb 20; 174(8):488-90. PubMed ID: 22348670 [Abstract] [Full Text] [Related]
14. Nonalcoholic fatty liver disease: new treatments. Hardy T, Anstee QM, Day CP. Curr Opin Gastroenterol; 2015 May 20; 31(3):175-83. PubMed ID: 25774446 [Abstract] [Full Text] [Related]
15. Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Akshintala D, Chugh R, Amer F, Cusi K. ; 2000 May 20. PubMed ID: 31310460 [Abstract] [Full Text] [Related]
16. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Corey KE, Rinella ME. Dig Dis Sci; 2016 May 20; 61(5):1387-97. PubMed ID: 26942734 [Abstract] [Full Text] [Related]
17. Therapies in non-alcoholic steatohepatitis (NASH). Oseini AM, Sanyal AJ. Liver Int; 2017 Jan 20; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626 [Abstract] [Full Text] [Related]
18. Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials. An J, Sohn JH. Clin Mol Hepatol; 2023 Feb 20; 29(Suppl):S268-S275. PubMed ID: 36537018 [Abstract] [Full Text] [Related]
19. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Clore J, Mills AS. Clin Gastroenterol Hepatol; 2004 Dec 20; 2(12):1107-15. PubMed ID: 15625656 [Abstract] [Full Text] [Related]
20. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS. Curr Vasc Pharmacol; 2020 Dec 20; 18(2):172-181. PubMed ID: 30961499 [Abstract] [Full Text] [Related] Page: [Next] [New Search]